(Q37574433)

21 August 2017

1 reference

title

Treatment of retinal diseases with VEGF antagonists (English)

1 reference

21 August 2017

R O Schlingemann

1

1 reference

21 August 2017

A N Witmer

series ordinal

2

1 reference

21 August 2017

publication date

1 January 2009

1 reference

Progress in Brain Research

21 August 2017

published in

1 reference

21 August 2017

volume

175

1 reference

21 August 2017

page(s)

253-267

1 reference

Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Retinal and choroidal neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Mechanisms of angiogenesis and arteriogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Vascular development and disorders: molecular analysis and pathogenic insights

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Neovascular age-related macular degeneration: potential therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Aldose reductase: a window to the treatment of diabetic complications?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Ischemia-driven angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Vascular endothelial growth factor induces endothelial fenestrations in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Molecular and biological properties of the vascular endothelial growth factor family of proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Pegaptanib for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Vascular Endothelial Growth Factor-Induced Migration of Vascular Smooth Muscle Cells in Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Role of VEGF-A in endothelial phenotypic shift in human diabetic retinopathy and VEGF-A-induced retinopathy in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina: new insights into the pathogenesis of capillary nonperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

1 reference

7 January 2021

Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Performance-based and self-assessed measures of visual function as related to history of falls, hip fractures, and measured gait time. The Beaver Dam Eye Study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Protein kinase C activation and the development of diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Panretinal photocoagulation and retinal oxygenation.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Testing intravitreal toxicity of bevacizumab (Avastin).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Pathogenetic potential of leukocytes in diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Role of leukocytes in diabetic microcirculatory disturbances

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

VEGF-A and the induction of pathological angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Analysis of glucose metabolism in diabetic rat retinas

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Evaluation of fluorescein-labeled autologous leukocytes for examination of retinal circulation in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Vascular endothelial growth factor in eye disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

In vivo angiogenic phenotype of endothelial cells and pericytes induced by vascular endothelial growth factor-A

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

Vascular endothelial growth factors and angiogenesis in eye disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

The structural basis of the blood-ocular barriers

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2809%2917517-9

7 January 2021

10.1016/S0079-6123(09)17517-9

Identifiers

DOI

1 reference

21 August 2017

1 reference